Sponsor hub

Massachusetts General Hospital clinical trial failures

Review 167 stopped clinical trials from Massachusetts General Hospital, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 10 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials167
Likely biological signals10
Shown below100

Dominant stop reasons

OPERATIONAL
116
OTHER/UNKNOWN
40
EFFICACY/FUTILITY
6
SAFETY
4
REGULATORY
1

Notable sponsors

Massachusetts General Hospital
167

Related phases

Phase II
56
Phase IV
45
Phase I
31
Unknown
20
Phase III
10

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04823624: MBG453 in Lower Risk MDS

Phase II Myelodysplastic Syndromes trial by Massachusetts General Hospital. Stop reason: OTHER/UNKNOWN.

The trial closed early due to changes in support for the study drug.

NCT03349775: Cardiometabolic Disease and Pulmonary Hypertension

Early Phase I Obesity trial by Massachusetts General Hospital. Stop reason: OPERATIONAL.

After discussion with the Data Safety Monitoring Board and NIH, the randomized clinical trial involving metformin vs. placebo is terminated due to slow enrollment in the setting of the COVID-19 pandemic.